| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3999714 | Urologic Oncology: Seminars and Original Investigations | 2015 | 11 Pages |
Abstract
These data confirm the expression of CD62L on urothelial carcinoma cells and suggest that CD62L may serve as biomarker to predict the presence of or risk for developing metastatic disease in patients with bladder cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Dharamainder Ph.D., Poornima M.D., Olga M.S., Shilpa Ph.D., Stavros Ph.D., Kevin P. Ph.D., Carol C. Ph.D., M.D., John A. M.D., M.S.,